1. Document Identity & Purpose
Document Type:
Medical Conference Abstract (Structured)
Intended Audience:
- Cardiology researchers and clinicians
- Medical affairs teams
- Clinical scientists in cardiometabolic disease
- Scientific congress abstract reviewers (AHA/ACC/ESC)
Context of Use:
This abstract is prepared for submission to a major cardiovascular congress (AHA/ACC/ESC). It highlights real-world evidence (RWE) on long-term cardiovascular outcomes associated with SGLT2 inhibitor use, demonstrating the ability to translate complex RWE findings into tight, data-focused scientific messaging under strict word limits.
Portfolio Positioning Statement:
This sample showcases MedLexis’ expertise in generating high-impact, publication-ready scientific abstracts that synthesize real-world evidence with precision, clarity, and regulatory alignment—meeting the expectations of pharmaceutical medical affairs and global cardiology congresses.
Project Overview
Overview
This sample demonstrates the development of a concise scientific abstract based on a real-world evidence research scenario involving long-term cardiovascular outcomes.
Objective
The objective was to communicate the essential research question, methodology, findings, and conclusion within a strict abstract format.
Intended Audience
Clinicians, researchers, scientific teams, conference audiences, and medical-affairs stakeholders requiring concise scientific communication.
Deliverable
A structured conference abstract organized around: Background → Methods → Results → Conclusion
What This Sample Demonstrates
- Scientific abstract writing
- Information compression
- Research-result presentation
- Strict word-count discipline
- Scientific clarity
- High-density communication
Sample Preview
2. Title
Long-term Cardiovascular Outcomes Associated With SGLT2 Inhibitor Use: A Real-World Evidence Analysis
3. Authors & Affiliations (Simulated)
- Robinson, MD¹; L. Chen, PhD²; M. Alvarez, MSc³;
MedLexis Scientific Research Unit⁴
- Division of Cardiovascular Medicine, Northbridge Medical Center, Boston, MA, USA
- Department of Epidemiology, Western Institute of Public Health, Seattle, WA, USA
- Center for Health Data Analytics, Madrid Institute of Biomedical Research, Madrid, Spain
- MedLexis Scientific Writing & Research Services, Global Operations
Corresponding Author:
A. Robinson, MD
Email: [email protected] (simulated)
4. Background (37 words)
Patients with type 2 diabetes face a high risk for long-term cardiovascular events. While randomized trials show cardiorenal benefits for SGLT2 inhibitors, their durability and effectiveness across diverse routine clinical practice populations require further real-world evidence evaluation.
5. Methods (68 words)
We conducted a multicenter, retrospective real-world evidence cohort analysis using electronic health records from 12 health systems (2015–2024).
Adults with type 2 diabetes who initiated an SGLT2 inhibitor were compared with matched patients receiving standard-of-care glucose-lowering agents.
The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included heart failure hospitalization and all-cause mortality. Follow-up extended up to 5 years.
We estimated adjusted hazard ratios using Cox proportional hazards models with propensity score weighting to balance baseline characteristics.
6. Results (105 words)
Among 38,412 patients (12,947 SGLT2 inhibitor users; 25,465 comparators) followed for a median of 4.2 years, SGLT2 inhibitor use was associated with a 23% lower risk of MACE (HR 0.77, 95% CI 0.71–0.83) and a 31% reduction in hHF (HR 0.69, 95% CI 0.62–0.76).
All-cause mortality was also significantly reduced (HR 0.82, 95% CI 0.74–0.90).
Mild genital infections were more frequent (3.8% vs 1.9%), whereas diabetic ketoacidosis events were rare (< 0.2% in both groups).
Subgroup analyses demonstrated consistent benefits across all age and renal function strata, with pronounced reductions in patients with baseline eGFR < 60 mL/min/1.73 m².
No unexpected safety signals were identified.
7. Conclusion (33 words)
In this large real-world cohort, SGLT2 inhibitor use was associated with sustained reductions in MACE, hHF, and all-cause mortality over a 5-year follow-up, supporting and extending randomized clinical trial findings to routine practice.
8. References
- Zinman B, Wanner C. SGLT2 inhibition and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
- McMurray JJV, Solomon SD. Cardiorenal benefits of SGLT2 inhibitors: Evidence across trials. Lancet. 2021;398:1233–1243.
- Lee S, Martinez R. Real-world cardiovascular outcomes with SGLT2 inhibitors: A global cohort analysis. Eur Heart J. 2023;44:1021–1030. (Simulated)
Access the full, expertly crafted article with in-depth insights and actionable strategies. Download now for clear, accurate, and impactful medical content.
How It Was Developed
Define → Research → Structure → Condense → Review → Deliver
The research content was organized around the essential information required for an abstract. The material was then condensed and refined to preserve scientific meaning while maintaining concise presentation.
Evidence & Quality Considerations
- Scientific structure
- Terminology consistency
- Data-focused communication
- Concise presentation
- Word-count control
- Editorial refinement
Conference-specific formatting and submission requirements should be confirmed against the target conference before submission.
Need Something Similar?
Need a clear, evidence-informed health article for a publication, healthcare organization, digital-health platform, or public audience?
